title: Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis.
abstract: OBJECTIVE
  To compare the efficacy and tolerability of once-weekly (OW) alendronate (ALN) 70 mg and raloxifene (RLX) 60 mg daily in the treatment of postmenopausal osteoporosis.
  
  
  METHODS
  This 12-month, randomized, double-blind study enrolled 456 postmenopausal women with osteoporosis (223 ALN, 233 RLX) at 52 sites in the United States. Efficacy measurements included lumbar spine (LS), total hip, and trochanter bone mineral density (BMD) at 6 and 12 months, biochemical markers of bone turnover, and percent of women who maintained or gained BMD in response to treatment. The primary endpoint was percent change from baseline in LS BMD at 12 months. Adverse experiences were recorded to assess treatment safety and tolerability.
  
  
  RESULTS
  Over 12 months, OW ALN produced a significantly greater increase in LS BMD (4.4%, P < 0.001) than RLX (1.9%). The percentage of women with > or = 0% increase in LS BMD (ALN, 94%; RLX, 75%; P < 0.001) and > or =3% increase in LS BMD (ALN, 66%; RLX, 38%; P < 0.001) were significantly greater with ALN than RLX. Total hip and trochanter BMD increases were also significantly greater (P < or =0.001) with ALN. Greater (P < 0.001) reductions in N-telopeptide of type I collagen and bone-specific alkaline phosphatase were achieved with ALN compared with RLX at 6 and 12 months. No significant differences in the incidence of upper gastrointestinal or vasomotor adverse experiences were seen.
  
  
  CONCLUSIONS
  ALN 70 mg OW produced significantly greater increases in spine and hip BMD and greater reductions in markers of bone turnover than RLX over 12 months. A greater percentage of women maintained or gained BMD on ALN than RLX. Both medications had similar safety and tolerability profiles.
authors.affiliation: St. Barnabas Osteoporosis & Metabolic Bone Disease Center, Livingston, NJ, USA.
authors.forename: Marjorie
authors.initials: M
authors.lastname: Luckey
authors.forename: Risa
authors.initials: R
authors.lastname: Kagan
authors.forename: Susan
authors.initials: S
authors.lastname: Greenspan
authors.forename: Henry
authors.initials: H
authors.lastname: Bone
authors.forename: R Douglas P
authors.initials: RD
authors.lastname: Kiel
authors.forename: James
authors.initials: J
authors.lastname: Simon
authors.forename: Jennifer
authors.initials: J
authors.lastname: Sackarowitz
authors.forename: Joanne
authors.initials: J
authors.lastname: Palmisano
authors.forename: Erluo
authors.initials: E
authors.lastname: Chen
authors.forename: Richard A
authors.initials: RA
authors.lastname: Petruschke
authors.forename: Anne E
authors.initials: AE
authors.lastname: de Papp
mesh_terms: D019386:Alendronate / Q000008:administration & dosage*; D000469:Alkaline Phosphatase / Q000097:blood; D015519:Bone Density; D003094:Collagen / Q000652:urine; D024042:Collagen Type I; D004311:Double-Blind Method; D004965:Estrogen Antagonists / Q000008:administration & dosage*; D005260:Female; D006615:Hip / Q000502:physiology; D006801:Humans; D008159:Lumbar Vertebrae / Q000502:physiology; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D010455:Peptides / Q000652:urine; D011446:Prospective Studies; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage*
chemical_list: D024042:Collagen Type I; D004965:Estrogen Antagonists; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D020849:Raloxifene Hydrochloride; D003094:Collagen; D000469:Alkaline Phosphatase; D019386:Alendronate